Australian Clinical Labs

Novel Genetic Tests And Digital Tools Will Capture Aging Demand

AnalystHighTarget

Not Invested

Consensus Narrative from 10 Analysts

Published

10 Jul 25

Updated

27 Aug 25

AnalystHighTarget's Fair Value

AU$4.73

42.8% undervalued

27 Aug

AU$2.71

-13.7%

8.4%

-13.7%

8.4%

Author's Valuation

AU$4.7

42.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$4.7

42.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

4.21%

Healthcare Services revenue growth rate

0.24%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$49.39m

Earnings '28

20.95x

PE Ratio '28

AU$1.03b

Market Cap '28

AU$1.03b

Market Cap '28

181.12m

No. shares '28

AU$5.71

Share Price '28

AU$5.71 Share Price '28

Discounted to 2025 @ 6.48% p.a.

AU$4.73

Fair Value '25